Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100U7ET
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Total assets¥95.9bnat 2024-06-30Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥57.7bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥37.1bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 586
ItemContextValueUnit
Profit loss IFRSPrior1YTDDuration-729014000JPY
Profit loss IFRSCurrentYTDDuration17925302000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration-729014000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration17925302000JPY
Profit loss IFRSPrior1YTDDuration-729014000JPY
Profit loss IFRSCurrentYTDDuration17925302000JPY
Basic earnings loss per share IFRSPrior1YTDDuration-5.62
Basic earnings loss per share IFRSCurrentYTDDuration138.30
Diluted earnings loss per share IFRSPrior1YTDDuration-5.62
Diluted earnings loss per share IFRSCurrentYTDDuration138.11
Profit loss IFRSPrior1YTDDuration-729014000JPY
Profit loss IFRSCurrentYTDDuration17925302000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration212258000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration469448000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration212258000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration469448000JPY
Other comprehensive income IFRSPrior1YTDDuration212258000JPY
Other comprehensive income IFRSCurrentYTDDuration469448000JPY
Comprehensive income IFRSPrior1YTDDuration-516755000JPY
Comprehensive income IFRSCurrentYTDDuration18394750000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration-516755000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration18394750000JPY
Comprehensive income IFRSPrior1YTDDuration-516755000JPY
Comprehensive income IFRSCurrentYTDDuration18394750000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember3956738000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember4524436000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-607334000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember23848337000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember319287000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember32041465000JPY
Equity IFRSPrior2YearInstant32041465000JPY
Profit loss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-729014000JPY
Profit loss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-729014000JPY
Profit loss IFRSPrior1YTDDuration-729014000JPY
Other comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember212258000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember212258000JPY
Other comprehensive income IFRSPrior1YTDDuration212258000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-729014000JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember212258000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass